🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "huge turning point" in the effort against superbug strains of the infection, according to researchers.

A Worldwide Health Concern

The sexually transmitted infection are increasing globally, with estimates suggesting in excess of 82 million infections per year. Notably increased rates are seen in Africa and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have reached a all-time high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an important and timely advancement in the context of increasing worldwide cases, the spread of superbugs and the extremely scarce treatment choices presently on offer.”

Health officials are particularly alarmed about the surge in drug-resistant strains. The WHO has listed it as a "critical concern". Recent surveillance revealed that the effectiveness of primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Treatment Options Gain Approval

Zoliflodacin, alternatively called a brand name, was authorized by the US FDA in mid-December for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Experts anticipate that focused deployment of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, created by the drugmaker GSK, was also approved in close succession. This drug, which is additionally indicated for urinary tract infections, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to develop it.

“This milestone represents a huge turning point in the management of superbug gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Research Study Outcomes and Worldwide Availability

As per results detailed in a major medical journal, zoliflodacin eradicated more than 90% of uncomplicated infections. This puts it on an similar efficacy with the typical regimen, which involves a dual-drug approach. The trial included hundreds of participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the rights to make available and distribute the drug in a wide range of developing nations.

Clinicians directly involved have voiced hope. Access to a easy-to-administer therapy such as this is seen as a "game-changer" for managing the epidemic. This is considered crucial to reduce the burden of the illness for people and to halt the transmission of extremely resistant gonorrhoea around the world.